抗肿瘤药物临床研究进展
被引量:1
Advances in clinical research of anticancer drugs
摘要
近年来抗肿瘤药物的研究取得了飞速发展,使得肿瘤的治疗有了新的突破.随着分子生物学的发展,人们对肿瘤的认识不断深入,以及高通量筛选、计算机辅助设计、基因工程等新技术的应用,使得抗肿瘤药物的研究水平不断提高,在传统的抗肿瘤药物发展的同时,出现了一些新型的抗肿瘤药物,作用于肿瘤发生和转移的不同环节和新靶点.本文将对近年来临床抗肿瘤药物研究的一些热点作一综述.
出处
《临床药物治疗杂志》
2005年第2期5-7,共3页
Clinical Medication Journal
参考文献13
-
1[1]Herbst RS,Hess KR.Tran HT,et al.Phase I study of re combinant human endostatin in patients with advanced solid tumors.J Clin Onco,2002,20(18):3792~3803
-
2[2]Thomas JP,Arzoomanian RZ,A1berti D,et al.Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced so1id tumors.J Clin Onco,2003,21(2):223~231
-
3[3]Gingras D,Boivin D,Deckers C,et al.Neovasta tanovel antiangiogenic drug for cancer therapy.Anti Cancer Drugs,2003,l4(2):91~96
-
4[4]Falardeau P,Champagne P, et al.Nevoastat,a natural lyoccurring multifunction,antiangiogenic drug in phase Ⅲ clinical trials.Semin Oncol,2001,28(6):620~625
-
5[5]Cunningham D,Humblet Y,Siena S,et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer.N Engl J Med,2004,351:337~345
-
6[6]Fukuoka M,Yano S,Giaccone G,et al.Multi-institu tional randomised phase II trial of gefitinib for previously treated patients with advanced non sma1l cell lung cancer.J Clin Onco,2003,21:2237~2246
-
7[7]Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase Ⅲ trial- INTACT 1. J Clin Onco,2004,22:777~784
-
8[8]Herbst RS,Giaccone C,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer;A Phase Ⅲ trial-INTACT2.J Clin Onco,2004,22:785~794
-
9[9]Herbst RS Er1otinib(Tarceva):An update on the clinical trial program.Semin Onco 2003,30(Suppl.7):S34~S46
-
10[10]Schiller JH,New Directions In the treatment of solid tumors.Semin Onco.2003,30(suppl),S49~S55
同被引文献30
-
1Liu JS, Kuo SR, Mchugh MM, et al. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication though replication protein A inactivation[J]. J Biol Chem, 2000, 275(2): 1 391- 1 397.
-
2Awada A, Punt C J, Piccat M J, et al. Phase I study of Carzelesin (U- 80, 244) given (4-weekly) by intravenous bolus schedule[J]. Br J Cancer, 1999, 79(9 - 10): 1 454 - 1 461.
-
3Van Custsem E, Cunningham D, Maruun J, et al. Raltitrexed: current clinical status and future directions[J]. Ann Oncol, 2002, 13(4): 513- 522.
-
4Diaz- Rubio E. New chemotherapeutic advances in pancreatic, coloreetal, and gastric cancers [ J ]. Oncologist, 2004, 9 (3): 282 - 294.
-
5Vogelzang N J, Rusthoven J J, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003, 21(14): 2 636 -2 644.
-
6Baker DE. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the conlon or rectum[J]. Rev Gastroenterol Disord, 2003, 3 (1):31 -38.
-
7Countinho AK, Rocha LCM. Metastatic colorectal cancer: systemic treatment in the new millennium[J].Cancer Control, 2003, 10(3): 224- 238.
-
8Hartmann JT, Lipp HP. Toxicity of paltinum compounds[J] .Expert Opin Pharmacother, 2003, 4 (6) : 889 - 901.
-
9Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity[J]. Ann Oncol, 2002, 13(12): 1 841 - 1 851.
-
10Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancel[J ]. Oncologist, 2002, 7 (Suppl 5): 29 - 35.
-
1王淑萍.非抗肿瘤药物的抗肿瘤作用[J].中外医疗,2008,27(26).
-
2季名扬,宫美丽.分子靶向药物在胃肠道肿瘤综合治疗中的应用[J].中国卫生标准管理,2015,6(30):90-91.
-
3未来的药物剂型[J].化工文摘,2001(4):42-42.
-
4蒋正立.环孢素A制剂的研究进展[J].海峡药学,2005,17(4):8-10. 被引量:4
-
5吕建军,李波.临床前药物安全性评价中毒性病理学新技术的应用[J].药物分析杂志,2010,30(7):1336-1339. 被引量:1
-
6刘磊,田卫东.细胞凋亡在头颈部肿瘤放射治疗中的作用[J].口腔颌面外科杂志,2002,12(2):153-156. 被引量:3
-
7陆惠文.进口天然药物的质量及检验新技术的应用[J].中国药学杂志,2000,35(z1):19-20.
-
8谭清玉,张伟.计算机辅助设计在乳腺癌根治术后一期再造的临床应用[J].外科理论与实践,2008,13(2):175-177.
-
9许杨兵.原料药设备发展趋势与新技术的应用[J].中国药物经济学,2012,7(4):15-16. 被引量:2
-
10张志清,智丽敏.环孢素A新制剂研究进展[J].中国药学杂志,2002,37(9):643-646. 被引量:12